The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

Forest Laboratories

Status and phase

Completed

Phase 3

Conditions

Alzheimer's Disease

Treatments

Drug: Neramexane

Study type

Interventional

Funder types

Industry

Identifiers

NCT00090116

NER-MD-02

Details and patient eligibility

About

Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of moderate to severe Alzheimer's disease;
ambulatory patients

Exclusion criteria

folate deficiency;
clinically significant central nervous system disease other than Alzheimer's disease;
clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease